4th China Pharma Intellectual Property Summit 2019, Oct23-25 at Primus Hotel Shanghai Hongqiao China
4th China Pharma Intellectual Property Summit 2019 (CPIPS2019) organized by Shanghai YIP Events, Supported by Pharma IP Right Research Committee of Chinese Pharmaceutical Association and Bayhelix, which will be held on 23rd -25th , Oct this year at Primus Hotel Shanghai Hongqiao China.
As a dedicated event to pharmaceutical intellectual property, In the past three years we gathered more than 1000 attendees from relevant government departments(CNIPA/EPO/JPO/USPTO), industry associations, global and china local pharma/biotech companies, law firms, IP agencies, IP solution providers and so on. Our topics covered the IP protection in all over the world, include mainly China, Europe, US, Japan, South Korea and India. We hope CPIPS could be a good networking and sharing platform for Industry peers, in which we are promoting industry innovation and development.
Join US To Meet:
40+ Experts from Government & Authoritative Organizations Give Speeches
200+ Leading China Local & Multinational Pharmaceutical/Biotech Companies
80+ Leading China Local & Foreign Law Firms/IP Agencies
500+ Attendees
l Following the latest development of China Patent Law Amendment, IP Enforcement, Patent Linkage, Patent Term Extension Reform, and related Drug Regulatory Updates in China
l Addressing Challenges and Uncertainties under BREXIT, SPC, Unitary Patent & UPC in Europe
l Understanding the differences and updated requirements of examination standards, patent invalidation, patent litigation in China, US, EU, Japan and other key regions
l Learning IP management and practical experiences from Global and China leading pharma companies
l Meeting your clients/partners face to face and interact with 450+ industry peers
Part of Confirmed Speakers Snapshots :
Qingkui Zhang, Honorary Director, Pharma IP Right Research Committee
Hou Yao, Researcher of Chemical Appeal Department, The Patent Reexamination Board of the CNIPA
Yongshun Cheng, Director, Beijing Intellectual Property Institute
Yang Xu, Assistant General Counsel, Intellectual Property, BeiGene, Ltd.
Wenjun GengIP Director, CHIA TAI TIANQING PHARMACEUTICAL GROUP
Lifang Sun, IP Vice President, Luye Pharma Group
Qinghui Liu, Partner, Anjie Law Firm
Bo Xu, Judge, Beijing Intellectual Property Court
Feng Xu, IP Director for China and Asia, AstraZeneca
Wu Li, Senior Consultant, Anjie Law Firm
Wenping Chen, Partner, King & Wood Mallesons
Tina Tai, Partner, King & Wood Mallesons
Michael Wise, Partner, Perkins Coie LLP
Shashank Upadhye, Partner, Upadhye Cwik LLP
Carl A. Morales, Partner, Dechert LLP
Gang Wang, Associate, Dechert LLP
Yite John Lu, Partner, Irell & Manella LLP
Andy Zhang, Senior Corporate Counsel, Intellectual Property, Sunovion Pharmaceutical
Teresa Lavoie, Principal, Fish & Richardson P.C.
Dr. Joerg Thomaier, Head of IP, Bayer Group
Chris Goddard, Partner, Dehns Patent and Trade Mark Attorneys
Peter L. Dolan, Strategy and Business Development Senior Director, Sanofi
Dr. Christof Bull, Associate General Patent Counsel, UCB Biopharma
Daisy Wu, IP Director, Shanghai Henlius Biotech, Inc.
Mahendra B. Thakre, Senior General Manager, Global IP, Mylan Laboratories Limited
Toru Matsuoka, Deputy Director, Examination Standards Office, JPO
Poonam Raghuvanshi, Vice President & Head of IP, Dr. Reddy's Laboratories Ltd.
Ilseok Alban Kang, Patent Attorney, FirstLaw P. C.
Gustavo Morais, Partner, IP Agent, Dannemann Siemsen
Ana Carneiro, Partner, IP Agent, Dannemann Siemsen
Yongfeng Zheng, Legal Director and Vice Dean of Research Institute, Tasly Holding Group
Topics Will be Presented and Discussed:
l The Present Situation & Trends of Patent Examination and Hotspot Issues in Reexamination and Invalidation Cases in China
l IP Enforcement and Protection in China
l Interpretation: The Latest Drug Regulatory Policies and Implementing Details from National Medical Products Administration
l The Impact of Patent Linkage and Patent Term Extension System on the Industry
l Patent Protection of Biological Sequences
l Data Supplementation for Chemical and Biotech Patents
l IP Challenges and Strategy from Perspective of Innovative Pharma Company under New Environment in China
l Hot Issues and Difficulties in Pharma Patent Infringement Litigation Cases
l Evaluation of Inventive Step of Pharmaceutical Compound Inventions
l Latest Developments of IPR and Recent Patent Invalidation Cases in US
l The Strategy of ANDA Filers to Challenge Patents Under a PIV Certification and Recent ANDA Litigation Cases Study
l Identifying the Loss of Exclusivity (LoE) of a U.S. Pharmaceutical Patent Portfolio
l U.S. Biosimilar Patent Litigation: Strategies and Trends Panel Discussion
l IP Issues Related to US and China (Strategy and Challenges)
l UPC and UPS - Why does it Make Sense for Europe and What Could be the Impact of Brexit?
l Recent European Regulatory Developments on Supplementary Protection Certificates (SPCs)
l Biosimilars in US,EU and China: Where Are We Now and Where Are We Going?
l How to Build a Successful Licensing Program and Other Strategies for IP Monetization
l Patent System and Practice of Medical Fields and Patent Term Extension in Japan
l IP Management & Practices Adopted by Generic Drug Manufacturers from India
l Patent System for Pharmaceutical Invention in South Korea
l Life Sciences: IP and Regulatory Environment in Brazil and selected Latin American Jurisdictions
l Current Patenting Situation of Chinese Medicine in China & Analysis from Reexamination and Invalidation Cases
l Rethinking of Patent Creative Evaluation for Traditional Chinese Medicine
l Relevant Issues on the Protection of Trade Secrets of Traditional Chinese Medicine
l IP Challenges and Strategy for Chinese Medicine ‘Going Out’
Past CPIPS Information please visit below:
3rd China Pharma Intellectual Property Summit 2018
2nd China Pharma Intellectual Property Summit 2017
China Pharma Intellectual Property Summit 2016
Contact Organizer to get the latest agenda for this year or visit conference website at www.pharmaip.cn or www.yipevents.com
Johnson Li
Conference Manager
Tel: 86 21 6142 1083
Mobile: 86 189 1779 8290
Email: johnson.leung@yipevents.com
Web: www.yipevents.com
